Oculopharyngeal muscular dystrophy

Overview

Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic disorder characterised by muscle weakness that worsens over time. The name describes the main areas of the body affected: 'oculo' refers to the eyes, and 'pharyngeal' refers to the pharynx, or throat. This means individuals with OPMD often experience issues with their eyelids and swallowing [PMID:32066228].

Symptoms typically begin in adulthood, most often between the ages of 40 and 60, though onset can vary. It is a progressive condition, meaning the muscle weakness tends to increase over many years. While it primarily affects the muscles controlling eye movement and swallowing, other muscles in the body, such as those in the limbs, can also be affected in some individuals.

Symptoms & clinical features

The most common initial symptoms of OPMD are drooping eyelids, known as ptosis, and difficulty swallowing, medically termed dysphagia. Ptosis can sometimes be severe enough to affect vision, as the eyelids may cover the pupil. Dysphagia can range from mild difficulty with certain foods to more significant problems, leading to choking or aspiration (food or liquid entering the airway).

Over time, muscle weakness may extend to other areas. This can include weakness in the muscles of the tongue and face, and sometimes in the neck or limb muscles, particularly in the shoulders and hips. The progression of symptoms is often slow and can vary considerably between individuals. While OPMD is primarily a muscle disorder, it does not typically affect intelligence or sensation.

Video: Genetics 101

Affected organs

The primary organs affected in OPMD are skeletal muscles, particularly those of the eyes and throat. The extraocular muscles, which control eye movement, can be involved, leading to limitations in eye gaze. The levator palpebrae superioris muscles, responsible for lifting the eyelids, are weakened, causing ptosis.

The muscles of the pharynx and oesophagus, which are crucial for swallowing, are also significantly affected. This can lead to impaired food passage from the mouth to the stomach. In some cases, proximal limb muscles (those closer to the body's centre, like the shoulders and hips) may also show weakness, although this is less consistent and typically milder than the eye and throat symptoms.

Brain

Central nervous system involvement

Nervous system

Peripheral nerve involvement

Risks & severity

OPMD is a progressive condition, and its severity can vary significantly among affected individuals, even within the same family. While symptoms usually begin in adulthood, typically between 40 and 60 years of age, the rate of progression and the extent of muscle involvement are not uniform [PMID:32066228].

The most significant risks are associated with dysphagia, which can lead to weight loss, malnutrition, and aspiration pneumonia, a serious lung infection caused by inhaling food or liquid [PMID:29662057]. While OPMD is generally not considered a life-limiting condition on its own, complications arising from severe swallowing difficulties can impact overall health and quality of life. The condition is rare, but exact prevalence figures for the UK are not well established.

Genetic causes

Oculopharyngeal muscular dystrophy is caused by changes in the PABPN1 gene. This gene provides instructions for making polyadenylate-binding protein nuclear 1. This protein is involved in the process of creating other proteins and maintaining the stability of genetic material within cell nuclei. In individuals with OPMD, a specific genetic alteration occurs in the PABPN1 gene: an expansion of a GCN triplet repeat sequence.

This expansion leads to the production of an altered protein that forms abnormal clumps within muscle cells. These protein aggregates are thought to interfere with normal cell function, ultimately causing the progressive muscle weakness characteristic of OPMD [PMID:29662057]. Understanding this genetic change is crucial for accurate diagnosis and for research into potential therapies.

Inheritance pattern

Oculopharyngeal muscular dystrophy is inherited in an autosomal dominant pattern. This means that a person only needs to inherit one copy of the altered gene from one parent to develop the condition. If a parent has OPMD, there is a 50% chance with each pregnancy that their child will also inherit the condition, regardless of the child's sex.

Autosomal dominant inheritance means the condition affects males and females equally. Even if one parent has OPMD, their children who do not inherit the altered gene will not develop the condition and cannot pass it on to their own children. Family history often shows the condition appearing in multiple generations.

Diagnosis & testing

The diagnosis of OPMD is typically suspected based on characteristic clinical symptoms, such as progressive ptosis and dysphagia, particularly when they appear in adulthood and there is a family history consistent with autosomal dominant inheritance. A specialist, such as a neurologist, will usually conduct a clinical assessment.

Confirmation of OPMD is made through genetic testing. This involves a blood test to analyse DNA for the expanded GCN triplet repeat in the PABPN1 gene. In the UK, genetic testing for neuromuscular conditions like OPMD is part of the NHS Genomic Medicine Service and is typically accessed via specialist referrals. The relevant NHS National Genomic Test Directory R-code for OPMD (R446) would be used by the referring clinician to request this testing.

Management & lifestyle

While there is currently no cure for OPMD, management focuses on alleviating symptoms and improving quality of life. Regular follow-up with a neurologist is important to monitor the progression of the condition and address new symptoms. Management strategies are multidisciplinary and tailored to the individual's specific needs.

For ptosis, surgical correction (blepharoptosis repair) can help lift the eyelids and improve vision. For dysphagia, speech and language therapists can provide advice on swallowing techniques, dietary modifications, and exercises. In more severe cases of dysphagia, procedures like cricopharyngeal myotomy (a surgical cut to the muscle at the top of the oesophagus) or gastrostomy (placement of a feeding tube directly into the stomach) may be considered to prevent aspiration and maintain nutrition. Genetic counselling is also an important part of the management pathway, offering support and information to individuals and families.

UK care pathway

In the UK, individuals suspected of having Oculopharyngeal muscular dystrophy typically enter the NHS Genomic Medicine Service pathway. This usually begins with a referral from a GP to a specialist, such as a neurologist, who can confirm the clinical diagnosis and arrange genetic testing. Genetic testing for rare conditions like OPMD is available through the National Genomic Test Directory, using specific R-codes (such as R446 for OPMD) to ensure the correct tests are performed.

Following a confirmed diagnosis, patients are often referred to clinical genetics services. Here, they can receive comprehensive genetic counselling, which provides detailed information about the condition, its inheritance pattern, and implications for family members. Multidisciplinary teams, which may include neurologists, speech and language therapists, dietitians, and ophthalmologists, work together to provide ongoing care and support.

Related conditions

It is important to differentiate OPMD from other conditions that might present with similar symptoms, particularly drooping eyelids or swallowing difficulties. Other forms of muscular dystrophy, such as myotonic dystrophy or limb-girdle muscular dystrophies, can sometimes have overlapping features but are caused by different genetic mechanisms and have distinct patterns of muscle involvement.

Neurological conditions like myasthenia gravis, which also causes muscle weakness and can affect the eyelids and swallowing, can be considered during diagnosis. OPMD also needs to be distinguished from age-related ptosis or dysphagia, which are not genetic. Accurate genetic testing is crucial to ensure a correct diagnosis and appropriate management plan.

Frequently asked questions

References

1. Salort-Campana E, Attarian S. Late-onset myopathies. Current opinion in neurology. 2024. PMID: 39017649